Acicot Ophthalmic Solution 0.1%

Acicot Ophthalmic Solution 0.1% is a dexamethasone-based eye drop manufactured by ACI Limited. Designed to treat inflammatory eye conditions, it offers anti-allergic and anti-exudative effects. Priced at ৳65.00 per unit, this ophthalmic solution is cost-effective for managing ocular inflammation caused by allergies or post-surgical interventions.

This dexamethasone formulation inhibits phospholipase A2, reducing prostaglandin synthesis and neutrophil infiltration. Effective within 15-30 minutes of application, its therapeutic action lasts 4-6 hours. Common indications include allergic conjunctivitis, keratitis, scleritis, and post-operative care after cataract surgery. Patients should store it at room temperature, avoiding light exposure.

Dosage Guidelines:

• Solution: 1 drop 3-5 times daily in the conjunctival sac
• Severe cases: Up to hourly application initially
• Ointment: Apply 3-4 times daily (if prescribed)

Potential side effects include reversible intraocular pressure elevation in predisposed patients. While safe for most users, pregnant women should use it only if benefits outweigh fetal risks. No significant drug interactions have been reported, making Acicot a reliable choice among ophthalmic solutions in Bangladesh.

Solution: 1 drop 3-5x daily (up to hourly in acute cases). Ointment: Apply 3-4x daily. Close eyes for 1-2 mins post-application. Taper dose upon improvement. Avoid prolonged use (>2 weeks) without medical supervision.

In predisposed patients, application of corticosteroids for a period of several weeks may cause a reversible rise in intraocular pressure. Pressure measurements at regular intervals are therefore essential.

Pregnancy Category C: Use only if benefits outweigh risks. Animal studies show fetal harm. Lactation: Potential excretion in breast milk.

Avoid in active infections. Discontinue if no improvement in 3 days. Prevent dropper contamination. Apply 15 mins before contact lenses.

Geriatric: Monitor IOP closely. Pediatric: Limited safety data. Hepatic/Renal: No dose adjustment needed.

Overdose through local or accidental oral administration is not likely.